TFRC and sarcoma: Similarly, analysis of a TCGA dataset of sarcoma samples revealed that gene amplification or high mRNA expression of SHARPIN and/or TFRC is associated with a significantly shorter OS (no alteration group, n = 207, median OS: 76.4, 95% CI: 54.2–88.5; SHARPIN amplification or HIGH group, n = 15, median OS: 26.4, 95% CI: 9.3–N/A; TFRC AMP or HIGH group, n = 15, median OS: 65.4, 95% CI: 13.6–N/A; SHARPIN and TFRC AMP or HIGH group, n = 4, median OS: 3.88, 95% CI: 0.6–N/A, p < 0.05) (Figure 6E).